These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19418937)

  • 1. [Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)].
    Detry O; Delwaide J; De Roover A; Meunier P; Van Daele D; Lamproye A; Honoré P; Polus M
    Rev Med Liege; 2009 Mar; 64(3):168-70. PubMed ID: 19418937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R; Byrne MT; Tan A; Aucejo F
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
    Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of patients with hepatocellular carcinoma for sorafenib.
    Abou-Alfa GK
    J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
    Kim R; Menon N; Aucejo F
    Med Oncol; 2011 Dec; 28(4):1044-7. PubMed ID: 20635167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib, a systemic therapy for hepatocellular carcinoma.
    Méndez-Sánchez N; Vásquez-Fernández F; Zamora-Valdés D; Uribe M
    Ann Hepatol; 2008; 7(1):46-51. PubMed ID: 18376365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A
    Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
    Kudo M; Tateishi R; Yamashita T; Ikeda M; Furuse J; Ikeda K; Kokudo N; Izumi N; Matsui O
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():37-51. PubMed ID: 22873626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib: in hepatocellular carcinoma.
    Simpson D; Keating GM
    Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    Zhu AX; Clark JW
    Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
    [No Abstract]   [Full Text] [Related]  

  • 14. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
    Rowe IA
    Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
    [No Abstract]   [Full Text] [Related]  

  • 15. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
    Burak KW
    Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
    Carr BI; Carroll S; Muszbek N; Gondek K
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1739-46. PubMed ID: 21039835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
    Ranieri G; Gadaleta-Caldarola G; Goffredo V; Patruno R; Mangia A; Rizzo A; Sciorsci RL; Gadaleta CD
    Curr Med Chem; 2012; 19(7):938-44. PubMed ID: 22214462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib for advanced hepatocellular carcinoma: a systematic review.
    Ling-lin Z; Li M; Jin-hui T; Ke-hu Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):51-7. PubMed ID: 21375938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
    Cabibbo G; Rolle E; De Giorgio M; Genco C; Pressiani T; Spada F; Sacco R;
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1807-16. PubMed ID: 22049974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.